NTLA
Intellia Therapeutics, Inc.9.12
-0.02-0.22%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.06BP/E (TTM)
-Basic EPS (TTM)
-4.25Dividend Yield
0%Recent Filings
8-K
Trial pause after adverse event
Intellia Therapeutics paused dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nexiguran ziclumeran on October 27, 2025, after a patient in MAGNITUDE experienced Grade 4 liver transaminases and elevated bilirubin on October 24, triggering protocol criteria. Over 650 ATTR-CM patients and 47 ATTR-PN patients are enrolled, with more than 450 dosed. The company is monitoring the hospitalized patient, consulting experts, and engaging regulators to resume safely. Safety first halts progress.
10-Q
Q2 FY2025 results
Intellia Therapeutics posted Q2 revenue of $14.2M, up 105% y/y from $7.0M but down 21% q/q from $18.0M (derived), driven by Regeneron collaboration reimbursements for nex-z and lonvo-z programs. Operating expenses fell 15% y/y to $124.2M, reflecting January's 27% workforce cut and lower stock-based comp, narrowing the operating loss to $110.0M from $139.0M y/y; net loss improved to $101.3M or $(0.98) diluted EPS from $147.0M or $(1.52) y/y, reconciling to 103.7M weighted shares. YTD revenue dipped 14% y/y to $30.9M amid AvenCell adjustments, with net loss at $215.6M or $(2.08) EPS versus $254.4M or $(2.64) y/y. Cash and marketable securities stood at $630.5M, funding operations into mid-2027; no debt. Phase 3 trials for nex-z and lonvo-z advance on schedule. Patent disputes pose ongoing IP risks.
8-K
Q2 results show trial acceleration
Intellia Therapeutics reported Q2 2025 results, highlighting accelerated enrollment in Phase 3 trials for nexiguran ziclumeran in ATTR amyloidosis and lonvoguran ziclumeran in hereditary angioedema, with MAGNITUDE expanding to 1,200 patients for a robust dataset. Cash stood at $630.5 million, funding operations into mid-2027. Dr. David Lebwohl retires as CMO effective August 7, 2026, but stays until a successor arrives. Enrollment surges fast.
8-K
Positive lonvo-z Phase 1 data
Intellia Therapeutics unveiled three-year Phase 1 data for lonvo-z, its CRISPR-based therapy for hereditary angioedema, showing a 98% mean reduction in monthly attack rates across all 10 patients, with everyone attack-free and treatment-free for a median of 23 months. The therapy proved well-tolerated, featuring only mild infusion reactions and no serious adverse events. Phase 3 HAELO screening wrapped ahead of schedule, with results due in early 2026 and a BLA filing planned for 2026. Yet regulatory hurdles loom large.
8-K
2025 Equity Plan approved
Intellia Therapeutics' stockholders approved the 2025 Equity Incentive Plan on June 11, 2025, succeeding the 2015 plan to support ongoing equity awards. The annual meeting also elected William Chase, Georgia Keresty, and John M. Leonard as class III directors for three-year terms, ratified Deloitte & Touche as auditors, and backed annual say-on-pay votes. Stockholders favored yearly executive compensation reviews. This bolsters talent retention amid biotech competition.
AUTL
Autolus Therapeutics plc
1.60-0.02
BEAM
Beam Therapeutics Inc.
26.76-0.07
CLLS
Cellectis S.A.
4.06-0.73
CRSP
CRISPR Therapeutics AG
55.97-0.28
EDIT
Editas Medicine, Inc.
2.51+0.07
GNTA
Genenta Science S.p.A.
1.32-0.10
INAB
IN8bio, Inc.
1.50-0.10
KRRO
Korro Bio, Inc.
8.22+0.26
KYTX
Kyverna Therapeutics, Inc.
10.24-0.58
SNTI
Senti Biosciences, Inc.
1.25+0.04